Targeted DNA sequencing has recently been demonstrated to be a comprehensive tool to detect multiple types of oncogenic alterations, including relevant oncogenic kinase fusions in NSCLC (i.e., ROS1, ALK, RET). The gene discussed is ALK; the disease is non-small cell lung carcinoma.